

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box/  
Multipack**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Doxybactin 200 mg tablets

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains:

Doxycycline (as doxycycline hyclate)      200 mg

**3. PACKAGE SIZE**

10 tablets  
20 tablets  
30 tablets  
100 tablets

10 x 10 tablets

**4. TARGET SPECIES**

Dogs.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Oral use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Shelf life of divided tablets: 3 days.

**9. SPECIAL STORAGE PRECAUTIONS**

Store below 30°C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Dechra Regulatory B.V.

**14. MARKETING AUTHORISATION NUMBERS**

Vm 50406/4020

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  
UNITS {NATURE/TYPE}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Doxybactin



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Doxycycline (as doxycycline hyclate)      200 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Shelf life of divided tablets: 3 days.

**PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

**PACKAGE LEAFLET**

**1. Name of the veterinary medicinal product**

Doxybactin 200 mg tablets for dogs

**2. Composition**

Each tablet contains:

**Active substances:**

200 mg doxycycline as doxycycline hyclate

Yellow with brown spots, round and convex flavoured tablet with a cross-shaped break line on one side. The tablets can be divided into 2 or 4 equal parts.

**3. Target species**

Dogs.



**4. Indications for use**

Treatment of the following conditions caused by bacteria sensitive to doxycycline:

Rhinitis (inflammation of the nasal mucosa) caused by *Bordetella bronchiseptica* and *Pasteurella* spp.;

Bronchopneumonia (lobular inflammation of the lungs) caused by *Bordetella* spp. and *Pasteurella* spp.;

Interstitial nephritis (inflammation of part of the kidney tissue) caused by *Leptospira* spp.

**5. Contraindications**

Do not use in cases of hypersensitivity to tetracyclines or to any of the excipients.

**6. Special warnings**

Special precautions for safe use in the target species:

The veterinary medicinal product should be administered with caution to animals with dysphagia (difficulty swallowing) or diseases accompanied with vomiting, since administration of doxycycline hyclate tablets has been associated with oesophageal erosion (injuries to the gullet). In order to reduce the likelihood of oesophageal irritation as well as other gastrointestinal side effects, the veterinary medicinal product should be administered together with food.

Special care should be taken when administering the veterinary medicinal product to animals with liver disease, since increases in hepatic enzymes have been documented in some animals after doxycycline treatment.

The veterinary medicinal product should be administered with caution to young animals, since tetracyclines as a class may cause permanent discolouration of the teeth, when administered during tooth development. However, human literature indicates that doxycycline is less likely than other tetracyclines to cause these abnormalities, due to its reduced ability to bind calcium.

Use of the veterinary medicinal product should be based on identification and susceptibility testing of the target pathogens. If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at local / regional level. Use of the veterinary medicinal product should be in accordance with official, national and regional antimicrobial policies. Use of the veterinary medicinal product deviating from the instructions given in the leaflet may increase the prevalence of bacteria resistant to doxycycline and may decrease the effectiveness of treatment with other tetracyclines, due to the potential for cross-resistance.

As tablets are flavoured store tablets out of reach of the animals in order to avoid accidental ingestion.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tetracyclines may cause hypersensitivity (allergy) reactions.

People with known hypersensitivity to tetracyclines should avoid contact with the veterinary medicinal product.

If you develop symptoms following exposure such as skin rash, seek medical advice immediately and show the package leaflet to the physician.

Doxycycline may cause gastrointestinal disturbances after accidental ingestion, especially by children. To avoid accidental ingestion, particularly by a child, unused tablet parts should be returned to the open blister space and inserted back into the carton. In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

#### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Tetracyclines as a class can retard foetal skeletal development (fully reversible) and cause discolouration of the deciduous teeth. However, evidence from human literature suggests that doxycycline is less likely to cause these abnormalities than other tetracyclines. Use only according to the benefit-risk assessment by the responsible veterinarian.

#### Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with bactericidal antibiotics such as penicillins and cephalosporins. Oral absorbents and substances containing multivalent cations such as antacids and iron salts should not be used from 3 hours before to 3 hours after the administration of doxycycline. The half-life of doxycycline is reduced by concurrent administration of antiepileptic drugs such as phenobarbital and phenytoin.

#### Overdose:

In cases of overdose no symptoms are to be expected other than those mentioned in the section on adverse events.

## 7. Adverse events

Dogs:

|  |   |
|--|---|
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | Gastrointestinal disorder (e.g. Vomiting, Diarrhoea, Oesophagitis (inflammation of the oesophagus)), Dental discolouration <sup>a</sup><br>Hypersensitivity reaction<br>Photosensitivity <sup>b</sup> , Photodermatitis <sup>b</sup><br>Developmental bone and joint disorders <sup>c</sup> |
|--|---|

<sup>a</sup> In very young animals. By the formation of a tetracycline-calcium phosphate complex.

<sup>b</sup> An abnormal skin reaction after exposure to intense daylight.

<sup>c</sup> Retardation of skeletal growth of young animals (reversible upon discontinuation of therapy) is known to occur with use of other tetracyclines and might occur following administration of doxycycline.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## 8. Dosage for each species, routes and method of administration

Oral use.

The recommended dose for dogs is 10 mg doxycycline per kg bodyweight per day. The majority of routine cases are expected to respond after between 5 and 7 days of therapy. Therapy should continue for 2 to 3 days beyond the clinical cure for acute infections. In chronic or refractory cases, a longer course of therapy, up to 14 days, may be required. In dogs with interstitial nephritis due to leptospirosis, treatment for 14 days is recommended. To ensure a correct dosage body weight should be determined as accurately as possible.

The following table is intended as a guide to dispensing the veterinary medicinal product at the standard dose rate of 10 mg per kg bodyweight per day.


| Body weight       | Dose mg | Doxybactin 50 mg |     | Doxybactin 200 mg |     | Doxybactin 400 mg |
|-------------------|---------|------------------|-----|-------------------|-----|-------------------|
| 0.75 kg – 1.25 kg | 12.5    | ▤                |     | -                 |     | -                 |
| >1.25 kg – 2.5 kg | 25      | ◐                |     | -                 |     | -                 |
| >2.5 kg – 3.75 kg | 37.5    | ◑                |     | -                 |     | -                 |
| >3.75 kg – 5 kg   | 50      | ⊕                |     | -                 |     | -                 |
| >5 kg – 6.25 kg   | 62.5    | ⊕ ▤              |     | -                 |     | -                 |
| >6.25 kg – 7.5 kg | 75      | ⊕ ◐              |     | -                 |     | -                 |
| >7.5 kg – 10 kg   | 100     | ⊕ ⊕              |     | -                 |     | -                 |
| >10 kg – 12.5 kg  | 125     | ⊕ ⊕ ◐            |     | -                 |     | -                 |
| >12.5 kg – 15 kg  | 150     | ⊕ ⊕ ⊕            |     |                   |     | -                 |
| >15 kg – 20 kg    | 200     | -                |     | ⊕                 |     | -                 |
| >20 kg – 25 kg    | 250     | ⊕                | AND | ⊕                 |     | -                 |
| >25 kg – 30 kg    | 300     | -                |     | ⊕ ◐               |     | -                 |
| >30 kg – 35 kg    | 350     | -                |     | ⊕ ◑               |     | -                 |
| >35 kg – 40 kg    | 400     | -                |     | -                 |     | ⊕                 |
| >40 kg – 45 kg    | 450     | ⊕                | AND |                   |     | ⊕                 |
| >45 kg – 50 kg    | 500     | -                |     | ◐                 | AND | ⊕                 |
| >50 kg – 60 kg    | 600     | -                |     | ⊕                 | AND | ⊕                 |
| >60 kg – 70 kg    | 700     | -                |     | ⊕ ◐               | AND | ⊕                 |
| >70 kg – 80 kg    | 800     | -                |     | -                 |     | ⊕ ⊕               |

▤ = ¼ Tablet    ◐ = ½ Tablet    ◑ = ¾ Tablet    ⊕ = 1 Tablet

### 9. Advice on correct administration

Tablets should be administered together with the food (see section Special warnings).

Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.



2 equal parts: press down with your thumbs on both sides of the tablet.

4 equal parts: press down with your thumb in the middle of the tablet.

#### **10. Withdrawal periods**

Not applicable.

#### **11. Special storage precautions**

Keep out of the sight and reach of children.

Store below 30°C.

Do not use this veterinary medicinal product after the expiry date which is stated on the package after Exp.

The expiry date refers to the last day of that month.

Shelf life of divided tablets: 3 days.

#### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

#### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

#### **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 50406/4020

Pack sizes:

Cardboard box of 1, 2, 3 or 10 blisters of 10 tablets.

Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets.

Not all pack sizes may be marketed.

**15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

**16. Contact details**

Marketing authorisation holder:

Dechra Regulatory B.V.  
Handelsweg 25  
5531 AE Bladel  
The Netherlands

Manufacturer responsible for batch release:

Lelypharma B.V.  
Zuiveringsweg 42  
8243 PZ Lelystad  
The Netherlands


Genera d.d.  
Svetonedeljska cesta 2  
Kalinovica  
10436 Rakov Potok  
Croatia

Local representatives and contact details to report suspected adverse reactions:

Dechra Veterinary Products Limited  
Sansaw Business Park  
Hadnall  
Shrewsbury  
Shropshire  
SY4 4AS  
United Kingdom  
Tel: +44 (0) 1939 211200

**17. Other information**

POM-V



Divisible tablet

*Gavin Hall*  
Approved: 04 November 2025